Interview with Sugiyama Masakazu, President of ACK
페이지 정보
작성자ajinomo 조회 71 작성일 24-07-08 13:00본문
 |  |
Introduction:
Congratulations on your new role as the President of ACK. Could you introduce yourself and share some of your background prior to
joining ACK?
joining ACK?
I am delighted to be appointed as the president of ACK and excited to take on new challenges with the team. I have been with Ajinomoto Co., Inc. for
27 years, spending 17 years in bioprocess R&D. After that, I worked in R&D planning for six years, promoting value co-creation with B2B partners.
Then, I worked in the Amino Acids Department, managing the cell culture media business for four years, before joining ACK in July 2024.
27 years, spending 17 years in bioprocess R&D. After that, I worked in R&D planning for six years, promoting value co-creation with B2B partners.
Then, I worked in the Amino Acids Department, managing the cell culture media business for four years, before joining ACK in July 2024.
Vision and Goals:
As the new leader of ACK, what are your vision and goals for the company over the next five years? What changes and growth will you
foresee?
foresee?
As a member of the Ajinomoto Group, our purpose is to contribute to the well-being of people and society through AminoScience®. We have expanded our business with many customers, including South Korea's Celltrion and Prestige Biologics, as well as Japan's Chugai Pharmaceutical and Daiichi
Sankyo. We aim to deepen these partnerships further. Additionally, we are committed to enhancing the well-being of more people by providing
solutions to customers worldwide, including in China, India, Europe, and the United States.
Sankyo. We aim to deepen these partnerships further. Additionally, we are committed to enhancing the well-being of more people by providing
solutions to customers worldwide, including in China, India, Europe, and the United States.
Communication with the Team:
What was your first impression of the ACK team? How do you plan to communicate and foster collaboration within the team?
As ACK continues to grow, I see that our members are lively and passionate about taking on new challenges. Each person demonstrates leadership in their own work, respects one another, and works as One Team to create value for our customers. I value direct dialogue with each individual and aim to further develop ACK's people-centric culture. By sharing our thoughts and passion for realizing our purpose, we will move forward together to achieve
our goals.
our goals.
Current Projects and Challenges:
What are the major projects currently underway at ACK? What do you see as the key challenges these projects are facing?
We have established the CELLiST Solution Center (CSC) in Korea and Shanghai to provide our products and solutions to more customers. We are
also preparing to establish a CSC in India, which is experiencing rapid growth. Our challenge is to enhance our capabilities to provide tailor-made
solutions that meet the diverse needs of customers in each region. Additionally, we need to strengthen our production, supply, and quality control
systems to better meet our customers' needs.
also preparing to establish a CSC in India, which is experiencing rapid growth. Our challenge is to enhance our capabilities to provide tailor-made
solutions that meet the diverse needs of customers in each region. Additionally, we need to strengthen our production, supply, and quality control
systems to better meet our customers' needs.
Technological Innovation and R&D:
ACK places a high value on continuous technological innovation and research and development. How do you plan to steer ACK's R&D
efforts and foster technological advancements?
efforts and foster technological advancements?
In close cooperation with the research institute of Ajinomoto Co., Inc., we are developing a wide range of products and solutions, from cell culture
media for antibody drug production to vaccine production and cell and gene therapy. We aim to enhance our ability to provide solutions, including
quality and regulatory compliance, in these expanding modalities.
media for antibody drug production to vaccine production and cell and gene therapy. We aim to enhance our ability to provide solutions, including
quality and regulatory compliance, in these expanding modalities.
Global Market Strategy:
What strategies do you have in place to strengthen ACK's position in the global market? Specifically, how do you plan to approach and
expand into international markets?
expand into international markets?
We aim to become the best partner for our customers by providing close communication and tailor-made solutions through the CELLiST Solution
Centers located at their sites and by leveraging AminoScience®.
Centers located at their sites and by leveraging AminoScience®.
- 이전글Interview with Shinhye Kim, Manufacturing Group Leader 24.07.18
- 다음글Interview with Yuta Nakai, President of ACK 24.06.25
댓글목록
등록된 댓글이 없습니다.
SAMPLE